On 17 July 2024, Celltrion reported that its Remsima SC (infliximab subcutaneous injection), biobetter to Remsima® (IV product), a biosimilar to Janssen’s Remicade® (infliximab), has recorded European market share of over 20% for the first time since its 2020 EU launch. This is based on data for Q1 2024 from pharmaceutical market research firm IQVIA and is partly attributed to successful Remsima SC tenders in Germany, Spain, the UK, Italy and France.
According to Celltrion’s press release, EU market share for its biosimilars Vegzelma (bevacizumab) and Uplyma (adalimumab) has also increased in Q1 2024, with that for Vegzelma almost doubling compared to Q1 2023 and that for Uplyma reaching double digits for the first time.
Celltrion has recently won tenders to supply Remsima SC in Denmark (April 2024) and Norway (February 2024).